MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/inf.0000000000005195

Медицинская библиотека · The Pediatric infectious disease journal · 2026

Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial.

Natukunda Eva, Szubert Alex J, Bwakura-Dangarembizi Mutsa, Mulenga Veronica, Doerholt Katja, Lugemwa Abbas, Byaruhanga Spencer, Nambi Esther, Ndebele Wedu, Nyathi Mary, Gibb Diana M, Ndeezi Grace, Walker Ann Sarah, Musoke Philippa, Musiime Victor

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Few studies have compared body composition changes in children living with HIV receiving integrase inhibitors or boosted protease inhibitors.

METHODS

Children switching to second-line antiretroviral therapy were randomized to dolutegravir (DTG), darunavir/ritonavir (DRV/r), atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r), and to tenofovir alafenamide (TAF) or standard of care (abacavir or zidovudine) using a factorial design. Body composition was measured using bioelectric impedance analysis over 96 weeks. Associations between baseline characteristics and changes in fat mass, fat-free mass, muscle mass and body fat percentage were estimated using robust regression with multivariable fractional polynomial selection (exit P = 0.05).

RESULTS

Eight hundred forty-one participants were included in the analysis. Females compared with males had greater fat accrual (+4.66% body fat, +1.32 kg fat mass; both P < 0.001). Compared with LPV/r, ATV/r and DTG exposures were associated with higher fat-free mass [+0.85 kg (95% confidence interval: 0.43-1.27) and +0.79 kg (0.37-1.21) respectively] and muscle mass [+0.82 kg (0.41-1.23) and +0.82 kg (0.42-1.22), respectively] (all P < 0.001). TAF and DRV/r exposures were associated with higher fat mass [+0.32 kg (0.12-0.52) P = 0.002; +0.33 kg (0.04-0.61) P = 0.025, respectively]. Prior nevirapine exposure was also associated with greater fat accrual [+0.36 kg (0.13-0.58) vs. efavirenz, P = 0.002]. Baseline CD4 and viral load, time on first-line antiretroviral therapy, and site were also associated with composition changes.

CONCLUSIONS

DTG and ATV/r were associated with greater gains in fat-free mass and muscle mass than LPV/r, while DRV/r, TAF and prior nevirapine exposure were associated with fat mass accrual. Fat gain may initially reflect return to health but sustained increases may have metabolic implications. These findings suggest the need to monitor fat compartments with long-term exposure.

Для цитирования: Natukunda Eva, Szubert Alex J, Bwakura-Dangarembizi Mutsa, Mulenga Veronica, Doerholt Katja, Lugemwa Abbas, Byaruhanga Spencer, Nambi Esther, Ndebele Wedu, Nyathi Mary, Gibb Diana M, Ndeezi Grace, Walker Ann Sarah, Musoke Philippa, Musiime Victor. Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial.. The Pediatric infectious disease journal. 2026. DOI: 10.1097/inf.0000000000005195.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.